The University of Southampton
University of Southampton Institutional Repository

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review
Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review
AIMS: To assess the clinical effectiveness of pegaptanib sodium and ranibizumab for neovascular age-related macular degeneration (AMD). METHODS: A systematic review of randomised controlled trials (RCTs) identified through searching 12 electronic databases, bibliographies and consultation with experts and manufacturers. RCTs were eligible if they assessed the effects of pegaptanib or
ranibizumab with best supportive care, sham injection or photodynamic therapy (PDT) on patients with subfoveal choroidal neovascularisation associated with wet AMD and examined outcomes including visual acuity and adverse events. RESULTS: Three RCTs of ranibizumab (MARINA, ANCHOR, FOCUS) and two of pegaptanib (VISION study) met the inclusion criteria. The RCTs included patients with different lesion types. The studies showed statistically significant benefit on different measures of visual acuity for patients receiving pegaptanib, ranibizumab or
ranibizumab with PDT compared to control (sham injection, PDT or sham injection with PDT) after 12 months. These differences appeared to be clinically significant. Although adverse events were common among those receiving pegaptanib
or ranibizumab, they were considered mild to moderate in nature. Meta-analysis of ranibizumab trials and indirect comparison of the two drugs were not possible due to differences in the study populations' lesion types. However, results from the RCTs of ranibizumab tended to show a greater effect on visual acuity than results
from the RCT of pegaptanib. CONCLUSIONS: Pegaptanib and ranibizumab appear to slow or stop the progression of neovascular AMD. Uncertainty remains over the relative benefits of pegaptanib compared with ranibizumab and other unlicensed drugs (eg, Avastin), due to the nature of the evidence. Head-to-head RCTs and economic evaluations comparing these alternatives are needed.
0007-1161
1177-1182
Takeda, A.L.
695119fc-0471-417f-9364-6542ef35cd86
Colquitt, J.
741c69a3-d9e0-4f10-b457-e496541e7915
Clegg, A.J.
838091f5-39df-4dbe-a369-675b26f2301b
Jones, J.
5ca0d91a-d5f9-4d00-834d-46c550240a13
Takeda, A.L.
695119fc-0471-417f-9364-6542ef35cd86
Colquitt, J.
741c69a3-d9e0-4f10-b457-e496541e7915
Clegg, A.J.
838091f5-39df-4dbe-a369-675b26f2301b
Jones, J.
5ca0d91a-d5f9-4d00-834d-46c550240a13

Takeda, A.L., Colquitt, J., Clegg, A.J. and Jones, J. (2007) Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. British Journal of Ophthalmology, 91 (9), 1177-1182. (doi:10.1136/bjo.2007.118562). (PMID:17475698)

Record type: Article

Abstract

AIMS: To assess the clinical effectiveness of pegaptanib sodium and ranibizumab for neovascular age-related macular degeneration (AMD). METHODS: A systematic review of randomised controlled trials (RCTs) identified through searching 12 electronic databases, bibliographies and consultation with experts and manufacturers. RCTs were eligible if they assessed the effects of pegaptanib or
ranibizumab with best supportive care, sham injection or photodynamic therapy (PDT) on patients with subfoveal choroidal neovascularisation associated with wet AMD and examined outcomes including visual acuity and adverse events. RESULTS: Three RCTs of ranibizumab (MARINA, ANCHOR, FOCUS) and two of pegaptanib (VISION study) met the inclusion criteria. The RCTs included patients with different lesion types. The studies showed statistically significant benefit on different measures of visual acuity for patients receiving pegaptanib, ranibizumab or
ranibizumab with PDT compared to control (sham injection, PDT or sham injection with PDT) after 12 months. These differences appeared to be clinically significant. Although adverse events were common among those receiving pegaptanib
or ranibizumab, they were considered mild to moderate in nature. Meta-analysis of ranibizumab trials and indirect comparison of the two drugs were not possible due to differences in the study populations' lesion types. However, results from the RCTs of ranibizumab tended to show a greater effect on visual acuity than results
from the RCT of pegaptanib. CONCLUSIONS: Pegaptanib and ranibizumab appear to slow or stop the progression of neovascular AMD. Uncertainty remains over the relative benefits of pegaptanib compared with ranibizumab and other unlicensed drugs (eg, Avastin), due to the nature of the evidence. Head-to-head RCTs and economic evaluations comparing these alternatives are needed.

Full text not available from this repository.

More information

Published date: September 2007
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 345714
URI: http://eprints.soton.ac.uk/id/eprint/345714
ISSN: 0007-1161
PURE UUID: cfce0875-b18f-41d4-97a2-8d6e30ff89c8

Catalogue record

Date deposited: 28 Nov 2012 16:40
Last modified: 16 Jul 2019 21:48

Export record

Altmetrics

Contributors

Author: A.L. Takeda
Author: J. Colquitt
Author: A.J. Clegg
Author: J. Jones

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×